- Home
- EBS vs SLDB Comparison
EBS vs SLDB Comparison
Compare EBS & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- SLDB
- Stock Information
- Founded
- EBS 1998
- SLDB 2013
- Country
- EBS United States
- SLDB United States
- Employees
- EBS N/A
- SLDB N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EBS Health Care
- SLDB Health Care
- Exchange
- EBS Nasdaq
- SLDB Nasdaq
- Market Cap
- EBS 423.6M
- SLDB 464.1M
- IPO Year
- EBS 2006
- SLDB 2018
- Fundamental
- Price
- EBS $9.11
- SLDB $6.23
- Analyst Decision
- EBS Strong Buy
- SLDB Strong Buy
- Analyst Count
- EBS 2
- SLDB 10
- Target Price
- EBS $13.50
- SLDB $15.00
- AVG Volume (30 Days)
- EBS 969.4K
- SLDB 1.3M
- Earning Date
- EBS 10-29-2025
- SLDB 11-05-2025
- Dividend Yield
- EBS N/A
- SLDB N/A
- EPS Growth
- EBS N/A
- SLDB N/A
- EPS
- EBS 2.53
- SLDB N/A
- Revenue
- EBS $851,600,000.00
- SLDB N/A
- Revenue This Year
- EBS N/A
- SLDB N/A
- Revenue Next Year
- EBS $19.24
- SLDB N/A
- P/E Ratio
- EBS $3.63
- SLDB N/A
- Revenue Growth
- EBS N/A
- SLDB N/A
- 52 Week Low
- EBS $4.02
- SLDB $2.41
- 52 Week High
- EBS $12.73
- SLDB $7.37
- Technical
- Relative Strength Index (RSI)
- EBS 54.66
- SLDB 55.00
- Support Level
- EBS $9.07
- SLDB $5.83
- Resistance Level
- EBS $10.10
- SLDB $6.79
- Average True Range (ATR)
- EBS 0.49
- SLDB 0.47
- MACD
- EBS 0.01
- SLDB 0.04
- Stochastic Oscillator
- EBS 53.00
- SLDB 59.68
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.